TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion

Mojdeh Shakiba(Memorial Sloan Kettering Cancer Center), Paul Zumbo(Cornell University), Gabriel Espinosa-Carrasco(Memorial Sloan Kettering Cancer Center), Laura Menocal(Memorial Sloan Kettering Cancer Center), Friederike Dündar(Cornell University), Sandra E. Carson(Cornell University), Emmanuel M. Bruno(Memorial Sloan Kettering Cancer Center), Francisco J. Sánchez‐Rivera(Memorial Sloan Kettering Cancer Center), Scott W. Lowe(Memorial Sloan Kettering Cancer Center), Steven Camara(Memorial Sloan Kettering Cancer Center), Richard P. Koche(Memorial Sloan Kettering Cancer Center), Vincent Reuter(Memorial Sloan Kettering Cancer Center), Nicholas D. Socci(Memorial Sloan Kettering Cancer Center), Benjamin M. Whitlock(Memorial Sloan Kettering Cancer Center), Fella Tamzalit(Memorial Sloan Kettering Cancer Center), Morgan Huse(Memorial Sloan Kettering Cancer Center), Matthew D. Hellmann(Memorial Sloan Kettering Cancer Center), Daniel K. Wells(Parker Institute for Cancer Immunotherapy), Nadine A. Defranoux(Parker Institute for Cancer Immunotherapy), Doron Betel(Cornell University), Mary Philip(Vanderbilt University Medical Center), Andrea Schietinger(Memorial Sloan Kettering Cancer Center)
The Journal of Experimental Medicine
December 22, 2021
Cited by 146Open Access
Full Text

Abstract

T cell receptor (TCR) signal strength is a key determinant of T cell responses. We developed a cancer mouse model in which tumor-specific CD8 T cells (TST cells) encounter tumor antigens with varying TCR signal strength. High-signal-strength interactions caused TST cells to up-regulate inhibitory receptors (IRs), lose effector function, and establish a dysfunction-associated molecular program. TST cells undergoing low-signal-strength interactions also up-regulated IRs, including PD1, but retained a cell-intrinsic functional state. Surprisingly, neither high- nor low-signal-strength interactions led to tumor control in vivo, revealing two distinct mechanisms by which PD1hi TST cells permit tumor escape; high signal strength drives dysfunction, while low signal strength results in functional inertness, where the signal strength is too low to mediate effective cancer cell killing by functional TST cells. CRISPR-Cas9-mediated fine-tuning of signal strength to an intermediate range improved anti-tumor activity in vivo. Our study defines the role of TCR signal strength in TST cell function, with important implications for T cell-based cancer immunotherapies.


Related Papers

No related papers found

Powered by citation graph analysis